Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment

Kidney and Blood Pressure Research

Volumn 28, Issue 5-6, 2005, Pages 295-301

  Siems, Werner ^a,f,g   Carluccio, Francesco ^b,f   Radenkovic, Sonja ^c,f   Grune, Tilman ^d   Hampl, Hannelore ^e  

^a Research Institute of Physiotherapy and Gerontology   (Serbia)

^b AUSL LE2 ^*  (Serbia)

^c UNIVERSITY OF NI   (Serbia)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f European Group of Clinical Research on Oxidative Stress   (Serbia)

^g KortexMed Institute of Medical Education   (Serbia)

Author keywords

Anemia; Erythropoietin; Hemodialysis; Hydroxynonenal; Lipid peroxidation; Malondialdehyde; Oxidative stress; Protein carbonyls

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE; CARBONYL DERIVATIVE; HEMOGLOBIN; LIPID; MALONALDEHYDE; PROTEIN DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

EID: 33644973334     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090184     Document Type: Article

References (45)

1. Trachtman H, Wilson D, Rao PS: The role of oxygen-free radicals in the development of chronic renal failure. Life Sci 1992;50:1877-1883.
2. Inagi R, Miyata T: Oxidative protein damage with carbohydrates and lipids in uremia: 'carbonyl stress'. Blood Purif 1999;17:95-98.
3. Peuchant E, Delmas-Beauvieux MD, Dubourg L, Thomas MJ, Perromat A, Aparicio M, Clerc M, Combe C: Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radical Biol Med 1997;22:313-320.
4. Sandau K, Pfeilschifter J, Brune B: The balance between nitric oxide and superoxide determines apoptotic and necrotic death of rat mesangial cells. J Immunol 1997;158:4938-4946.
5. Miyata T, Kurokawa K, van Ypersele de Strihou C: Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000;58(suppl 76):S120-S125.
6. Alfrey AC: Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis 1994;23:183-187.
7. Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic renal failure. Am J Kidney Dis 1997;29:465-477.
8. Loughrey CM, Young IS, Lightboy JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in hemodialysis. Q J Med 1994;87:679-683.
9. Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol Med 1991;11:81-128.
10. Kumagei T, Kawamoto Y, Nakamura Y, Hatayama I, Satoh K, Osawa T, Uchida K: 4-Hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem Biophys Res Commun 2000;273:437-441.
11. Liu W, Akhand AA, Kato M, Yokoyama I, Miyata T, Kurokawa K, Uchida K, Nakashima I: 4-Hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. J Cell Sci 1999;112:2409-2417.
12. Liu W, Kato M, Akhand AA, Hayakawa A, Suzuki H, Miyata T, Kurokawa K, Hotta Y, Ishikawa N, Nakashima I: 4-Hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 2000;113:635-641.
13. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, Osawa T: Activation of stress signalling pathways by the end product of lipid peroxidation: 4-hydroxynonenal is a potential inducer of intracellular peroxide production. J Biol Chem 1999;274:2234-2242.
14. Zarkovic N, Zarkovic K, Schaur RJ, Stolc S, Schlag G, Redl H, Waeg G, Borovic S, Loncaric I, Juric G, Hlavka V: 4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor. Life Sci 1999;65:1901-1904.
15. Uchida K, Stadtman ER: Selective cleavage of thioether linkage in proteins modified with 4-hydroxynonenal. Proc Natl Acad Sci USA 1992;89:5611-5615.
16. Uchida K, Stadtman ER: Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase: a possible involvement of intra- and intermolecular cross-linking reaction. J Biol Chem 1993;268:6388-6393.
17. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S: Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999;34:438-444.
18. Cavdar C, Camsari T, Semin I, Gonenc S, Acikgoz O: Lipid peroxidation and antioxidant activity in chronic hemodialysis patients with recombinant human erythropoietin. Scand J Urol Nephrol 1997;31:371-375.
19. Delmas-Beauvieux MD, Combe C, Peuchant E, Carbonneau MA, Bubourg L, de Precigout V, Aparicio M, Clerc M: Evaluation of red blood cell lipoperoxidation in hemodialyzed patients during erythropoietin therapy supplemented or not with iron. Nephron 1995;69:404-410.
20. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H: Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000;53(suppl 1):30-35.
21. Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJGM, Ehrich JHH, Siems WG: Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1997;13:2583-2587.
22. 2+ in rat liver microsomes. J Biochem 1982;208:129-140.
23. Grune T, Siems WG, Zollner H, Esterbauer H: Metabolism of 4-hydroxynonenal, a cytotoxic lipid peroxidation product, in Ehrlich mouse ascites cells at different proliferation stages. Cancer Res 1994;54:5231-5235.
24. Sommerburg O, Grune T, Klee S, Ungemach FR, Siems WG: Formation of 4-hydroxynonenal and further aldehydic mediators of inflammation during bromotrichloromethane treatment of rat liver cells. Mediators Inflamm 1993;2:27-31.
25. Wong SHY, Knight JA, Hopfer SM, Zaharia O, Leach CN, Sundermann FW: Lipid peroxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 1987;33:214-220.
26. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC: Protein carbonyl measurement by a sensitive ELISA method. Free Rad Biol Med 1997;23:361-366.
27. Sitte N, Merker K, von Zglinicki T, Grune T: Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Rad Biol Med 2000;28:701-708.
28. Westhuyzen J, Adams CE, Fleming SJ: Evidence for oxidative stress during in vitro dialysis. Nephron 1995;70:49-54.
29. Klutstein MW, Tzivoni D: Anaemia and heart failure: aetiology and treatment. Nephrol Dial Transplant 2005;20(suppl 7):vii7-vii10.
30. Wexler D, Silverberg D, Blum M, Sheps D, Keren G, Wollman Y, Schwartz D, Iaina A: Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant 2005;20(suppl 7):vii11-vii15.
31. Silverberg DS, Wexler D, Iaina A: The role of anemia in the progression of congestive heart failure: Is there a place for erythropoietin and intravenous iron? J Nephrol 2004;17:749-761.
32. Silverberg DS, Wexler D, Iaina A: The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardiorenal anemia syndrome. Perspect Biol Med 2004;47:575-589.
33. Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D, Keren G, Iaina A: The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome. Blood Purif 2004;22:277-284.
34. Silverberg DS, Wexler D, Blum M, Iaina A: The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003;60(suppl 1):S93-S102.
35. Siems WG, Sommerburg O, Grune T: Erythrocyte free radical and energy metabolism. Clin Nephrol 2000;53(suppl 1):9-17.
36. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP: A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid. J Neurochem 2002;68:255-264.
37. Siems WG, Hapner SJ, van Kuijk FJGM: 4-Hydroxynonenal inhibits Na+-K+-ATPase. Free Radical Biol Med 1996;20:215-223.
38. 2+ transport by 4-OH-2,3-trans-nonenal. Arch Biochem Biophys 1999;361:252-256.
39. Blasig IE, Grune T, Schoenheit K, Rohde E, Haseloff RF, Siems WG: 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol 1995;269:H14-H22.
40. Ruef J, Moser M, Bode C, Kuebler W, Runge MS: 4-Hydroxynonenal induces apoptosis, NF-kappa B-activation and formation of 8-isoprostane in vascular smooth muscle cells. Basic Res Cardiol 2001;96:143-150.
41. Salomon RG, Kaur K, Podrez E, Hoff HF, Krushinsky AV, Sayre LM: HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol 2000;13:557-564.
42. Mak S, Lehotay DC, Yazdanpanah M, Azevedo ER, Liu PP, Newton GE: Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. J Card Fail 2000;6:108-114.
43. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, Kraemer K, Hampl H, Sommerburg O: Oxidative stress in cardiorenal anemia syndrome: correlations and therapeutic possibilities. Clin Nephrol 2003;60(suppl 1):S22-S30.
44. Chen J, Henderson GI, Freeman GL: Role of 4-hydroxynonenal in modification of cytochrome c oxidase in ischemia/reperfused heart. J Mol Cell Cardiol 2001;33:1919-1927.
45. Eaton P, Li JM, Hearse DJ; Shattock MJ: Formation of 4-hydroxy-2-nonenal- modified proteins in ischemic rat heart. Am J Physiol 1999;276:H935-H943.